A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2006
11/21/2006	CA2302156C Methods for modulating the axonal outgrowth of central nervous system neurons
11/21/2006	CA2295867C Diglycerid and sterol based organometallic complexes and pharmaceutical compositions and dietetic products containing them
11/21/2006	CA2278409C Detergent cosmetic compositions and their use
11/21/2006	CA2275763C Combatting infection in delivery systems
11/21/2006	CA2272285C Amide derivatives and medicinal compositions thereof
11/21/2006	CA2258971C Use of a cosmetic compound for the treatment and prevention of acne rosacea
11/21/2006	CA2253736C Antimicrobial treatment for herpes simplex virus and other infectious diseases
11/21/2006	CA2247611C Method and composition for hair removal
11/21/2006	CA2247257C Novel aryl glycinamide derivatives, method of producing said derivatives and pharmaceutical compositions containing these compounds
11/21/2006	CA2243392C Use of a texaphyrin in the preparation of a medicament for use with a chemotherapeutic agent in cancer chemosensitization
11/21/2006	CA2220080C Method for making quinolone carboxylic acids or naphthyridine carboxylic acids in free base form
11/21/2006	CA2204478C Fluorinated vitamin d3 analogs
11/21/2006	CA2187523C Pyranone compounds useful to treat retroviral infections
11/21/2006	CA2178105C Skin care compositions containing dimethyl imidazolidinone and retinol or retinyl ester
11/21/2006	CA2168022C Vasoconstrictive substituted dihydropyranopyridines
11/21/2006	CA2166467C Sunscreen agents
11/21/2006	CA2164061C Cosmetic compositions containing lactate dehydrogenase inhibitors
11/21/2006	CA2140441C Inhibitors of c-amp phosphodiesterase and tnf
11/21/2006	CA2126518C Use of phenalkylamines
11/21/2006	CA2120619C Novel potent inducers of terminal differentiation and methods of use thereof
11/21/2006	CA2119070C Energy-supplementing saccharide source and its uses
11/20/2006	CA2611370A1 Inhibitors of vegf receptor and hgf receptor signaling
11/20/2006	CA2547274A1 Stable desloratadine compositions
11/20/2006	CA2508095A1 Preparation for external use on skin
11/20/2006	CA2508094A1 Composition for accelerating collagen synthesis
11/19/2006	CA2556536A1 Method of increasing intracellular concentrations of phosphate and increasing the force of muscular contractions
11/19/2006	CA2547127A1 Vectorization of dsrna by cationic particles and their use on skin model
11/19/2006	CA2547122A1 Vectorization of dsrna by cationic particles and topical use
11/18/2006	CA2547251A1 Fused pyrazolyl compounds for cancer treatment
11/17/2006	CA2549902A1 Cd44 polypeptides, polynucleotides encoding same, antibodies directed thereagainst and method of using same for diagnosing and treating inflammatory diseases
11/16/2006	WO2006122299A2 Fish oil in stabilized form
11/16/2006	WO2006122296A1 Isolation and structure of turbostatins 1-4
11/16/2006	WO2006122259A1 Optical resolution of 3-carbamoylmethyl-5-methyl hexanoic acid
11/16/2006	WO2006122255A1 Pregabalin free of isobutylglutaric acid and a process for preparation thereof
11/16/2006	WO2006122254A2 Stable micronized candesartan cilexetil and methods for preparing thereof
11/16/2006	WO2006122250A2 Antagonists of the vanilloid receptor subtype 1 (vr1) and uses thereof
11/16/2006	WO2006122230A1 P38 inhibitors and methods of use thereof
11/16/2006	WO2006122227A1 Glufosfamide combination therapy
11/16/2006	WO2006122216A2 Processes for production of phenolic 4-biphenylylazetidin-2-ones
11/16/2006	WO2006122207A1 6-hydrazinopurine 2'-methyl ribonucleosides and nucleotides for treatment of hcv
11/16/2006	WO2006122200A1 2,3-substituted fused bicyclic pyrimidin-4(3h)-ones modulating the function of the vanilloid-1 receptor (vr1)
11/16/2006	WO2006122186A2 1,4-diphenyl-3-hydroxyalkyl-2-azetidinone derivatives for treating hypercholestrolemia
11/16/2006	WO2006122160A2 Compositions of bakuchiol and methods of making the same
11/16/2006	WO2006122156A2 Compounds for modulating trpv3 function
11/16/2006	WO2006122154A2 Pyridone derivatives for modulating stress-activated protein kinase system
11/16/2006	WO2006122150A1 Modulators of indoleamine 2,3-dioxygenase and methods of using the same
11/16/2006	WO2006122137A1 1, 6 -dihydro- 1,3, 5, 6-tetraaza-as-indacene based tricyclic compounds and pharmaceutical compositions comprising same as inhibitors of ikk enzyme activity
11/16/2006	WO2006122104A1 Polyethylene glycol colonic purgative composition
11/16/2006	WO2006122035A2 Method for treating central pain syndrome or for inducing centrally generated pain in an animal model
11/16/2006	WO2006122021A1 Extrusion process for making compositions with poorly compressible therapeutic compounds
11/16/2006	WO2006122014A2 Bicyclic derivatives as modulators of ion channels
11/16/2006	WO2006122011A2 Thiazole compounds and methods of use
11/16/2006	WO2006122007A1 Compositions and methods for treatment for neoplasms
11/16/2006	WO2006122003A2 Diaryl-purine, azapurines and -deazapurines as non-nucleoside reverse transcriptase inhibitors for treatment of hiv
11/16/2006	WO2006121995A2 Methods for treating nephrolithiasis
11/16/2006	WO2006121979A2 Modified-release pharmaceutical compositions
11/16/2006	WO2006121964A2 Ophthalmic suspension comprising an ophthalmic drug, a poloxamine and a glycol tonicity-adjusting agent, use of said composition for the manufacture of a medicament for treating ophthalmic disorders
11/16/2006	WO2006121963A2 Suspension formulations comprising an active principle, a poloxamer or meroxapol surfactant and a glycol, its use for the manufacture of a medicament for treating ophthalmic disorders
11/16/2006	WO2006121962A1 N-thiolated 2-oxazolidone antibiotics
11/16/2006	WO2006121960A2 Methods and sequences to suppress primate huntington gene expression
11/16/2006	WO2006121943A2 Method for the treatment of magnesium and potassium deficiencies
11/16/2006	WO2006121941A2 Pharmaceutical compositions comprising imatinib and a release retardant
11/16/2006	WO2006121922A1 Monoamine re-uptake inhibitors and methods relating thereto
11/16/2006	WO2006121919A2 Methods of treating obsessive compulsive disorder
11/16/2006	WO2006121865A2 Methods of treating recurrent aphthous stomatitis
11/16/2006	WO2006121861A2 Biphenylazetidinone cholesterol absorption inhibitors
11/16/2006	WO2006121856A2 Pyrimidine-based non-nucleotide composition and method for inhibiting platelet aggregation
11/16/2006	WO2006121853A1 Combination therapy with sulodexide and a blood pressure reducing agent in the treatment of diabetic nephropathy
11/16/2006	WO2006121831A2 Hiv integrase inhibitors
11/16/2006	WO2006121822A1 USE OF β-LACTAMS FOR THE TREATMENTOF IBD AND GLAUCOMA
11/16/2006	WO2006121820A1 Phosphoramidate prodrugs for treatment of viral infection
11/16/2006	WO2006121742A2 Formulations of a src/abl inhibitor
11/16/2006	WO2006121715A1 Composition and method for repelling moles, voles and gophers
11/16/2006	WO2006121713A2 Delivery of tigecycline in the presence of heparin
11/16/2006	WO2006121708A1 Substituted beta-lactams and their use in medicine
11/16/2006	WO2006121684A2 Acyl hydrazones for treating cardiovascular diseases
11/16/2006	WO2006121666A2 Delivery of tigecycline in the presence of warfarin
11/16/2006	WO2006121648A2 Method for preparation of optionally 2-substituted 1,6-dihydro-6-oxo-4-pyrimidinecarboxylic acids
11/16/2006	WO2006121558A2 Method of prevention and treatment of aging, a related disorders and/or age-related manifestations includi r c erosis.
11/16/2006	WO2006121557A1 Pregabalin free of lactam and a process for preparation thereof
11/16/2006	WO2006121552A2 Abuse-resistant amphetamine prodrugs
11/16/2006	WO2006121548A2 Computer-implemented method and apparatus for diabetes management
11/16/2006	WO2006121535A1 Biodegradable polyacetals and methods
11/16/2006	WO2006121521A2 Soft tissue implants, anti-scarring agents, and therapeutic compositions
11/16/2006	WO2006121468A1 5-nitro-nucleoside compounds for treating viral infections
11/16/2006	WO2006121429A1 Clindamycin compositions and delivery system therefor
11/16/2006	WO2006121421A2 Methods and formulations for treating glaucoma
11/16/2006	WO2006121391A1 New compounds i
11/16/2006	WO2006121390A2 Benzoic acid derivatives that are modulators or agonists of glyr
11/16/2006	WO2006121389A1 Use of a neurokinin-2 receptor antagonist for treating or preventing detrusor overactivity
11/16/2006	WO2006121363A1 Eslicarbazepine acetate and methods of use
11/16/2006	WO2006121362A2 Use of antagonists of oxytocin and/or vasopressin in assisted reproduction
11/16/2006	WO2006121359A1 Epirubicine hydrochloride for treating hepatitis c virus
11/16/2006	WO2006121263A1 Use of paeonol for inhibiting angiogenesis or for enhancing radiosensitization
11/16/2006	WO2006121258A1 Composition comprising an obovatol having anti-anxiety activity
11/16/2006	WO2006121250A1 Pharmaceutical composition for the inhibition of lipogenesis comprising a regulator of prp19 expression
11/16/2006	WO2006121249A1 Cilostazol composite having increasing solubility, process for preparation and use thereof
11/16/2006	WO2006121232A1 Adjuvant comprising oligonucleotide and non toxic lps
11/16/2006	WO2006121219A1 Agent for controlling epithelial-mesenchymal transition
11/16/2006	WO2006121218A1 N,n-substituted 3-aminopyrrolidine compounds useful as monoamines reuptake inhibitors

1 ... 4002 4003 4004 4005 4006 4007 4008 4009 4010 4011 4012 4013 4014 4015 4016 4017 4018 4019 4020 4021 4022 ... 7860